PPT-Tumor Tumor

yrs Gender nd Location pons Diagnosis DIPGDMG H31 K27M Pretreatment no prior treatment Source biopsy Stage WHO grade IV   Genetic mutations HIST1H3B pK28M NTRK2 duplication exons 1116. Sam Kupfer and Joseph Ahmad. Background/Outline. Cancer is a group of diseases in which abnormal cells divide uncontrollably, forming tumors that interrupt the normal functioning of nearby cells and organs. By: . Weigang. . wang. , . sumanta. . goswami. , Erik . sahai. , . jeffrey. . b. . wyckoff. , Jeffrey E. . Segall. and John S. . Condeelis. Presented By: Lana . Awad. and Sebastian Lukjan. Motivation of research, why they did what they did…. Ondartet svulst = malign tumor = cancer = kreft. Godartet svulst = benign tumor. Navnsetting av tumorer. OPPRINNELSESVEV. BENIGN TUMOR. MALIGN TUMOR. Epitel. Plateepitel. Plateepitelpapillom. Plateepitelcarcinom. Ben Ho Park MD PhD. Johns Hopkins University. Financial Disclosures. I have financial relationships with commercial entities that are relevant to the content of this presentation.. Royalties from Horizon Discovery, LTD. Molecular Pathology Director: Frederick Nolte, Ph.D.. Cytogenetics and Molecular Genetics Director: . Daynna. Wolff, Ph.D.. Medical Director: Cynthia Schandl, M.D., Ph.D.. Associate Director: Julie Woolworth Hirschhorn, Ph.D.. By: . Weigang. . wang. , . sumanta. . goswami. , Erik . sahai. , . jeffrey. . b. . wyckoff. , Jeffrey E. . Segall. and John S. . Condeelis. Presented By: Lana . Awad. and Sebastian Lukjan. Motivation of research, why they did what they did…. xenograft. studies. May 18. th. MBSW 2016. Cong Li, Greg . Hather. , Ray Liu. Tumor . xenograft. study. A (rough) diagram of drug development process. Lead discovery/In-vitro study. In-vivo study. Clinical trial. RADIOLOGY ROTATION. LENA MESSINA. Pt is a 38 . y.o. . African American F with no significant PMH admitted to General Medicine with hypokalemia 2/2 to Cushing’s syndrome. She reports progressive swelling, weight gain and acne over the course of the past year. She has been amenorrhoeic for >6 months. Earlier labs showed hypothyroidism and hyperprolactinemia and the patient was started on levothyroxine and bromocriptine. She had multiple prior admissions for hypokalemia. She denies headaches, vision changes or urinary symptoms.. At diagnosis 80% of patients will present with metastasis.. Only 20% of these cases are clinically detectable.. Current imaging modalities are expensive and only detect established secondary tumors.. Séminaire. des . doctorants. William . Weens. BANG, . Inria. November. . 15th . 2011. Outline. Cancer. Systems Biology. Mathematical description. Application to liver tumor. Conclusion. Definition. 127 pISSN 2384-1095eISSN 2384-1109 Department of Radiology, Jeju National University Hospital, Jeju-si, KoreaDepartment of Pathology, Jeju National University Hospital, Jeju-si, Korea www.i-mri.org 12 What do we know about childhood brain tumors? What do we know about childhood brain tumors? Brain tumors represent about 25% of all childhood cancer diagnoses. patients under 20 years of age ea under Youn Wha Kim Sung Wan Kim Yong-Koo Park Chondromyxoid fibroma (CMF) is a relatively rare bone tumorthat was first described by Jaffe and Lichtensteinin 1948. Thistumor makes up less than 1% of all bon Intervista a Federico . Cappuzzo. Background:. Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) is associated with OS, PFS and ORR in pts with advanced NSCLC treated with atezolizumab (anti-PDL1, MPDL3280A; Spigel et al, Spira et al, ASCO 2015), indicating that PD-L1 expression on both TC and IC is important for anti-tumor immunity. However, these 2 distinct expression patterns suggest the existence of previously unidentified NSCLC subtypes with distinct immunologic profiles. .